QuidelOrtho Looks Mispriced If 2026's FCF Turnaround Materializes

QuidelOrtho's weakness is concentrated in post-COVID Point of Care and its deliberate exit from U.S. donor screening, but the rest of the portfolio is growing. Labs remains the main revenue engine at 55% of 2025 sales, while Immunohematology also expanded, indicating a healthier underlying mix. The article is more of a business-mix commentary than a new earnings catalyst.

Analysis

The key takeaway is not that QDEL is deteriorating uniformly, but that management is actively shrinking lower-quality revenue while the mix shifts toward more durable, recurring lab and blood-bank demand. That usually improves gross margin stability and multiple support even if reported top-line growth looks choppy, because investors tend to pay up for revenue visibility rather than headline growth alone. In other words, the market may be over-penalizing the company for deliberate pruning of businesses with weaker strategic value.

The beneficiaries are likely competitors in point-of-care and donor-screening niches that can absorb lost share, but the second-order effect is more important: QDEL’s remaining core businesses become easier to underwrite if the exit is truly complete within the next 1-2 quarters. That can also reduce inventory and working-capital drag, which matters for a name where cash conversion is often the real debate. If Labs is now the dominant engine, the stock should trade more like a steadier diagnostics platform than a COVID hangover story.

The contrarian risk is that investors may be anchoring on segment weakness without separating structural decline from intentional portfolio cleanup. If Labs and Immunohematology continue to expand over the next 2-3 quarters, the market could re-rate the name on mix improvement before absolute revenue growth fully normalizes. Conversely, if post-exit growth in the remaining portfolio stalls, the market will conclude this is not a pruning story but a shrinking one, and the de-rating could continue for another 6-12 months.

Key Decisions for Investors

• Initiate a tactical long QDEL on confirmation that the donor-screening exit is fully lapped, with a 2-3 quarter horizon; risk/reward is attractive if the market rerates on mix rather than growth, but stop out if Labs growth decelerates for two consecutive prints.
• Use a call spread in QDEL rather than outright equity for the next earnings cycle: upside is tied to narrative improvement and margin optics, while downside is capped if the market remains focused on legacy segment shrinkage.
• Pair trade: long QDEL / short a higher-beta diagnostics name with more exposure to transient demand, targeting a relative-value re-rating over 3-6 months as investors prefer recurring lab mix over volatile end-market exposure.
• Watch for a squeeze higher in QDEL if management signals stable or improving gross margin from the mix shift; that would be the catalyst for a 10-15% move over days to weeks as the market recalibrates quality of earnings.